InvestorsHub Logo
Followers 4
Posts 161
Boards Moderated 0
Alias Born 08/23/2015

Re: None

Sunday, 05/22/2016 2:14:04 PM

Sunday, May 22, 2016 2:14:04 PM

Post# of 432
PALO ALTO, Calif., April 15, 2016 (GLOBE NEWSWIRE) -- Carbylan Therapeutics (CBYL), a specialty pharmaceutical company, announced today that it has suspended further clinical development of Hydros-TA and that it is actively pursuing a strategic transaction, including a merger or acquisition of the company. As previously announced, Carbylan has engaged Wedbush PacGrow to act as its strategic financial advisor for this process.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent KALV News